Although the association between diabetes mellitus (DM) and pancreatic cancer is well described, temporal patterns of changes in fasting blood glucose (FBG) and body mass index (BMI) before pancreatic cancer diagnosis are not known.
INTRODUCTION
Pancreatic cancer has a dismal 5-year survival and is the fourth leading cause of cancer death in the United States (1) . At present, there is no accepted screening strategy for sporadic pancreatic cancer, and the disease is usually diagnosed at an advanced stage. Diabetes mellitus (DM) or hyperglycemia is common in pancreatic cancer patients (2, 3) ; further understanding of the temporal association between these two clinical conditions may provide opportunities for the early detection of pancreatic cancer.
Th e association between DM and pancreatic cancer is intriguing. On the one hand, there seems to be a modestly elevated risk of pancreatic cancer among individuals with long-standing DM; a recent meta-analysis reported a combined age-and sexadjusted odds ratio of 1.8 (95 % confi dence interval 1.7 -1.9) (4) .
Temporal Association of Changes in Fasting Blood Glucose and Body Mass Index With Diagnosis of Pancreatic Cancer
In contrast, there is increasing evidence suggesting that newonset DM ( < 2 years in duration) can be induced by pancreatic cancer. Approximately 40 -65 % of pancreatic cancer patients meet the criteria for DM at cancer diagnosis when evaluated by a measurement of fasting blood glucose (FBG) or by oral glucose tolerance tests (2, 3, 5, 6 ) . In addition, there is a close temporal association between the onset of DM and the diagnosis of pancreatic cancer (2, 3, 7) , with DM being new onset in the majority of cases. In our case -control study of 736 pancreatic cancer patients (diagnosed from 1981 through to 2004) and 1,875 age-and gender-matched controls, we found that the overall prevalence of DM in cases was signifi cantly higher than that in controls (40 % vs. 19 % , respectively; P < 0.001), and that DM was more oft en new onset among cases than among controls (52 % vs. 24 % , respectively; P < 0.001). When DM prevalence was evaluated in 12-month time intervals up to 60 months before the date of cancer diagnosis (or corresponding date among controls), the proportion of cases with DM, compared with that of controls, was higher during the − 36 to − 24-month, − 24 to − 12-month, and − 12 to + 1-month time intervals (3) . It has also been observed that new-onset DM usually resolves aft er tumor resection (2, 8, 9) .
For this study, we analyzed our case -control study data to investigate important additional questions regarding the role of two clinical correlates of DM in the time preceding diagnosis of pancreatic cancer, namely, FBG levels and body mass index (BMI). We have clinically observed that even individuals with long-standing diabetes exhibit a worsening of glucose control before pancreatic cancer diagnosis. We therefore hypothesized that the pattern of change in FBG diff ers among pancreatic cancer patients on the basis of their diabetic status (i.e., whether they met the glycemic criteria for DM) and the duration of DM (new onset vs. long standing).
Up to 80 % of pancreatic cancer patients develop either DM or hyperglycemia (2) . Understanding the diff erences in the clinical profi le of patients who do and do not develop DM may provide clues to the pathogenesis of pancreatic cancer-induced DM. In a recent case -control study of a diff erent sample of 512 pancreatic cancer patients and 933 matched controls, we observed that pancreatic cancer patients with DM at diagnosis, compared with those without DM, were more likely to be older, have a greater frequency of positive family history of DM, and a higher self-reported usual adult BMI (2) . We also examined these clinical correlates of DM in this study.
Obesity is recognized as a modest risk factor for pancreatic cancer (10) . It is also a common clinical observation that pancreatic cancer patients lose weight before diagnosis of their cancer. In this study, we determined the mean BMI at 12-month intervals for up to 60 months before the diagnosis of cancer in a pancreatic cancer cohort and compared it with the BMI over the same time period in a cohort of controls.
METHODS
Th is study was approved by the Mayo Clinic Foundation Institutional Review Board.
Ascertainment of cases and controls
As described earlier (3) , we searched the Mayo Diagnostic Index using the International Classifi cation of Diseases, Ninth Revision Clinical Modifi cation (ICD-9-CM) codes for pancreatic cancer (157.0 -157.9, excluding 157.4 (malignant neoplasm of islets of Langerhans)) (11) and retrieved cases seen at the Mayo Clinic, Rochester, MN, from 15 January 1981 through to 9 July 2004 and residing within a 120 mile radius of Rochester, the county seat of Olmsted County, MN. We further restricted this search to individuals who were either fi rst diagnosed at the Mayo Clinic or seen at the Mayo Clinic within 30 days of initial pancreatic cancer diagnosis. We reviewed the medical records of 1,172 cases thus identifi ed to confi rm the diagnosis of pancreatic adenocarcinoma (histological confi rmation present in 988 (84 % ) or compatible clinical presentation when histological evidence was not available in 184 (16 % )). For each case, we selected two Olmsted County residents who were seen at the Mayo Clinic in the same calendar year as the matched case ' s date of pancreatic cancer diagnosis (defi ned as the index date for each case and their control) and were matched to the case ' s gender (same) and age ( ± 1 year). Controls whose fi rst Mayo Clinic encounter was < 30 days from the index date were excluded.
Data collection and defi nitions
We electronically retrieved all outpatient FBG values in the Mayo records for 60 months before the index date for 1,172 cases and 2,344 controls. Of these individuals, the 736 cases and 1,875 controls who had at least one outpatient FBG value in the preceding 60 months or within 1 month aft er the index date (provided they received no treatment for pancreatic cancer) constituted the study population; further analyses were restricted to this subset of cases and controls. Inpatient and outpatient medical records were reviewed manually to abstract demographic and clinical data, including age, sex, parental history of DM, smoking status, and height (ht) and weight (wt) for calculating BMI (wt in kg / ht in m 2 ) at each FBG throughout the period from 60 months before and through 1 month aft er the index date. Th e average BMI value >2 years before the index date was defi ned as usual adult BMI. Th e patients were categorized as having DM if they had any FBG ≥ 126 mg per 100 ml (12) . DM duration was classifi ed as long standing if patients met the criteria for DM for more than 24 months before the index date, and as new onset if the fi rst date on which the patients met the criteria for DM was within 24 months before the index date and they had one or more earlier FBG values < 126 mg per 100 ml.
Data analysis
Both outpatient FBG and BMI values in cases and controls were grouped into 12-month intervals from 60 months before the index date until the index date. For patients without an FBG within the above specifi ed 60-month interval, we included FBG values up to 30 days aft er the index date, provided no surgical intervention had been carried out before the FBG measurements. Th erefore, the time intervals (windows) into which we categorized FBG and BMI values were − 60 to − 48 months, − 48 to − 36 months, − 36 to − 24 months, − 24 to − 12 months, and − 12 to + 1 month relative to index date.
All statistical analyses were carried out using SAS 9.1.3 (SAS Institute Inc, Cary, NC). We compared mean FBG and BMI values between cases and controls in each time window, and used linear regression analyses to assess the observed and predicted mean FBG and BMI in each time interval between cases and controls. We also compared the median FBG in each time window between cases and controls by overall DM status (diabetic vs. nondiabetic) and duration (new onset vs. long standing). Among pancreatic cancer cases ( n = 736), we compared the prevalence of conventional risk factors for DM (age, sex, parental history of DM, and usual adult BMI) between diabetic ( n = 296) and nondiabetic cases ( n = 440).
RESULTS
Th e demographic and clinical characteristics of the 736 cases and 1,875 controls included in the study are presented in Table 1 . Overall, in the time period − 60 to + 1 month relative to index, mean FBG was higher among cases (126.5 mg per 100 ml ± 50.5 mg per 100 ml) than among controls (104.7 mg per 100 ml ± 31.1 mg per 100 ml, P < 0.001), and mean BMI was lower among cases than among controls (26.7 ± 5.4 kg / m 2 vs. 27.3 ± 5.3 kg / m 2 , P = 0.01). As reported earlier (3) , in the analysis of DM preceding the index date, we found that a greater proportion of cases (296 of 736, 40.2 % ), compared with controls (360 of 1,875, 19.2 % , P < 0.0001), met the criteria for DM at any time in the 60 months before index.
Temporal pattern of FBG in cases and controls
Mean FBG values were similar between cases and controls in the − 60 to − 48 (102 mg per 100 ml vs. 100 mg per 100 ml, respectively; P = 0.34) and − 48 to − 36-month intervals (106 mg per 100 ml vs. 102 mg per 100 ml, respectively; P = 0.09), but mean FBG values were progressively higher for cases than for controls in the − 36 to − 24 (105 mg per 100 ml vs. 100 mg per 100 ml, respectively; P = 0.01), the − 24 to − 12 (114 mg per 100 ml vs. 102 mg per 100 ml, respectively; P = 0.001), and the − 12 to + 1 (123 mg per 100 ml vs. 102 mg per 100 ml, respectively; P < 0.0001)-month intervals ( Figure 1 ). Median FBG was similar among nondiabetic cases and nondiabetic controls in the − 60 to − 48 ( P = 0.72), the − 48 to − 36 ( P = 0.79), the − 36 to − 24 ( P = 0.81), and the − 24 to − 12 ( P = 0.1)-month intervals but was higher among nondiabetic cases (104 mg per 100 ml) than among nondiabetic controls (96 mg per 100 ml, P < 0.001) in the − 12 to + 1-month time interval ( Figure 2 ). Among diabetic patients with newonset DM ( < 2-years duration), the cases had a signifi cantly lower median FBG at the − 60 to − 48-month interval than did controls (96 mg per 100 ml vs. 109 mg per 100 ml, respectively; P = 0.005). Cases with new-onset DM also had a generally lower median FBG than did controls with new-onset DM 
Prevalence of conventional DM risk factors in pancreatic cancer-associated DM
Pancreatic cancer patients with DM, compared with those without DM, were older (mean age 70 ± 10 years vs. 68 ± 12 years, respectively; P = 0.02), had a higher usual adult BMI (28 ± 6 kg / m 2 vs. 26 ± 5 kg / m 2 , respectively; P < 0.001), and a greater frequency of positive parental history of DM (24 % vs. 14 % , respectively; P < 0.001) ( Table 2 ).
Temporal pattern of BMI in cases and controls
Compared with controls, cases had either similar ( − 60-to − 48-month interval, P = 0.07 and − 36-to − 24-month interval, P = 0.17) or higher mean BMI ( − 48-to − 36-month interval, P = 0.01 and − 36-to − 24-month interval, P = 0.04) ( Figure 3 ) . However, the mean BMI was lower among cases − 12 to + 1 month ( P < 0.001) before the index date.
DISCUSSION
Th e temporal association between changes in FBG and the diagnosis of pancreatic cancer has not been studied earlier. In this study, we evaluated the temporal pattern of FBG and BMI up to 60 months before the index date among 736 pancreatic cancer cases and 1,875 controls. FBG values were comparable in cases and controls in the − 60 to − 48 and − 48 to − 36-month time intervals. A progressive increase in FBG was seen among pancreatic cancer cases beginning 36 months before the diagnosis of cancer. Th is likely refl ects the development of new-onset diabetes in over 50 % of pancreatic cancer cases, as in the − 48 to − 36 ( P = 0.63), − 36 to − 24 ( P = 0.08), and − 24 to − 12 ( P = 0.03)-month intervals. However, the median FBG was signifi cantly higher among cases with new-onset DM than among controls with new-onset DM in the − 12 to + 1 month relative to index date (134 mg per 100 ml vs. 124 mg per 100 ml, respectively; P = 0.003).
Among diabetic patients with long-standing DM, cases and controls had similar median FBG at all time intervals except for − 12 to + 1 month, wherein the cases had a signifi cantly higher median FBG (178 mg per 100 ml vs. 146 mg per 100 ml, respectively; P = 0.002). was seen in our earlier studies (2, 3, 13) . Further, we and others have reported that new-onset DM that develops proximal to a diagnosis of pancreatic cancer improves aft er the resection of cancer (2, 8, 9) . Together, these data provide increasing evidence that new-onset DM associated with pancreatic cancer is induced by cancer. A signifi cant increase in FBG among all subsets (nondiabetic, new-onset, and long-standing DM) of pancreatic cancer cases, compared with controls, in the − 12-to + 1-month time interval suggests that pancreatic cancer is a profoundly diabetogenic state, which aff ects glucose metabolism in most, if not all, patients. Why then do some cancer patients develop DM and others do not? We propose that the development of diabetes in pancreatic cancer is the result of an interaction between the powerful diabetogenic milieu induced by the cancer and the susceptibility of the host to develop DM (14) . Data from this study suggest that those with an increased risk of developing DM, i.e., those who have conventional risk factors for DM, such as older age, obesity, and parental history of DM, are more likely to develop DM when pancreatic cancer develops compared with those who do not have any risk factors for DM. Th ese observations are similar to our recent report in a diff erent study population of pancreatic cancer cases with ( n = 240) and without ( n = 269) DM, wherein we found that the prevalence of conventional DM risk factors was signifi cantly higher among pancreatic cancer cases with DM than among those without DM (2) . Th e above observations also suggest that a distinction between type II DM and pancreatic cancerinduced DM, based solely on these clinical profi les, is likely to be diffi cult.
Weight loss, which is oft en profound, is an important and common symptom of pancreatic cancer. It is also well recognized that obesity is a modest risk factor for pancreatic cancer (10) . However, the temporal pattern of change in BMI before the diagnosis of pancreatic cancer, especially in comparison with age-and sex-matched controls, has not been investigated earlier. We found that pancreatic cancer patients have a progressive decline in their BMI starting approximately 12 months before the diagnosis of cancer. We have also clinically observed that pancreatic cancer patients with severe new-onset diabetes oft en rapidly lose weight many months before the onset of cancer-associated symptoms of cachexia (i.e., anorexia, fatigue, and weakness from muscle wasting). We reported earlier that the median time from the onset of the fi rst cancer-related symptom to the diagnosis of pancreatic cancer in our study population was 2 months (range 0.5 -36 months) (3) . In comparing the temporal trends in FBG and BMI among pancreatic cancer patients, our results suggest that the marked increase in FBG is concurrent with a signifi cant decline in BMI, particularly in the 12 months preceding the diagnosis of cancer.
Th e high prevalence of new-onset DM in pancreatic cancer suggests that the incidence of pancreatic cancer would be higher among individuals with new-onset DM than among the general population. In our earlier population-based study, individuals with new-onset DM had an approximately eightfold higher likelihood of being diagnosed with pancreatic cancer within 3 years of meeting the criteria for DM than does the general population (15) . However, pancreatic cancer patients do not have cancer-specifi c symptoms until late in the course of their disease and, consequently, studies that have screened individuals with new-onset DM who have cancer-specifi c symptoms reported mostly unresectable disease (16, 17) . For DM or hyperglycemia to be useful as a screening tool, it should be an early phenomenon that is associated with early-stage pancreatic cancer in asymptomatic individuals. Th e increase in FBG noted in this study and the higher prevalence of DM among cases (3) , compared with controls, nearly 12 -24 months before cancer diagnosis, suggest that new-onset hyperglycemia or DM is an early phenomenon in pancreatic cancer. Earlier studies based on a retrospective review of computed tomography scans have suggested that pancreatic cancer is either not detectable or is resectable on scans carried out >6 months before clinical diagnosis (18, 19) . We have reported earlier that approximately 50 % of stage I / II pancreatic cancer patients have DM2. Th erefore, new-onset diabetes not only defi nes a high-risk group for pancreatic cancer but also seems to be a marker of early, asymptomatic cancer. Its occurrence in nearly half of the patients with pancreatic cancer makes it an attractive screening criterion for early pancreatic cancer and suggests a ' window of opportunity ' for the detection of pancreatic cancer earlier using hyperglycemia as a marker.
However, presently, there remain signifi cant challenges to the use of hyperglycemia or a DM-based strategy in the screening for pancreatic cancer. Given the relatively low incidence of pancreatic cancer and the vast number of individuals with type II DM, screening for pancreatic cancer among asymptomatic individuals, in our opinion, is likely to require a two-step process (20) . New-onset DM seems to be an attractive fi rst sieve to enrich the general population and defi ne a subset that is at a higher risk for pancreatic cancer. However, the population of new-onset diabetics potentially linked to pancreatic cancer will need to be further enriched through a second sieve, which may be a unique clinical phenotype or biomarker for pancreatic cancer-induced DM (3, 20) . At present, a reliable biomarker for early pancreatic cancer or pancreatic cancer-induced DM is not available. Some putative mediators, such as pancreatic cancer-derived S100A8 N-terminal peptide (21) and connexin26 (22) , have been proposed, but data are preliminary. An improved understanding of the pathogenesis of pancreatic cancer-induced DM and the diff erences between this entity and type II DM are likely to be critical in the identification of a unique biomarker for pancreatic cancer-induced DM and its further validation as a screening tool.
An important limitation of our study is that many pancreatic cancer cases were seen at the Mayo Clinic only once, close to the date of diagnosis of their cancer, and therefore did not have earlier FBG values in our medical records. Th ese individuals contributed to the FBG values in the − 12-to + 1-month time interval. However, our results did not diff er when we restricted our analyses to cases that had been seen at least 6 months before the diagnosis of cancer, at a time when they were likely to be asymptomatic (data not shown). Moreover, our data on FBG and BMI are not longitudinal, i.e., patients did not have FBG and BMI values available at every time interval. Th erefore, we could not calculate the rate of change in either FBG or BMI between time intervals. However, given the low incidence of pancreatic cancer, a prospective cohort study examining these temporal trends is likely to be challenging to execute.
In conclusion, we report that pancreatic cancer patients, compared with age-and sex-matched controls, have a higher FBG beginning at 24 -36 months before the diagnosis of their cancer. Th is increase in FBG is concurrent with a gradual decline in BMI, especially up to 12 months before cancer diagnosis. Th e onset of hyperglycemia up to 24 months before the diagnosis of cancer defi nes a time frame in which the future use of biomarkers and risk stratifi cation may discriminate pancreatic cancer-associated diabetes from type II DM and facilitate an early diagnosis of pancreatic cancer.
